Amyloidosis and Carpal Tunnel Syndrome: An Update on Diagnostic and Management Considerations.

J Hand Surg Glob Online · May 2026 · Review

Laridaen J, Klena JC, Grandizio LC

Department of Orthopaedic Surgery, Geisinger Commonwealth School of Medicine, Geisinger MSKI, PA

Hand & Upper Extremity

SUMMARY — THE REDUCTIONHand surgeons should recognize carpal tunnel syndrome as a possible early marker of cardiac amyloidosis, though screening biopsy thresholds and costs during carpal tunnel release remain undefined.
Abstract, as published

In the past decade, hand and upper-extremity surgeons have become increasingly aware of the relationship between carpal tunnel syndrome and cardiac amyloidosis. Recent advances in medical management of cardiac amyloidosis in the form of disease-modifying therapies that improve survival have aided decreasing morbidity and in some cases, hand surgeons can detect evidence of amyloid deposition prior to clinical manifestations of cardiac disease. Despite improvements in biopsy techniques and analysis, there remain a number of controversies related to this condition that directly impact upper-extremity surgeons. At present, the number needed to screen for biopsy procedures during carpal tunnel release remains poorly defined relative to routine cancer screening protocols and there are a paucity of prior investigations assessing the costs associated with biopsy during carpal tunnel release. This narrative review aims to provide an update on diagnostic and management considerations for hand surgeons evaluating patients with carpal tunnel syndrome.

Featured in the 2026-06-19 issue.

← Innovations in Small Joint Arthroscopy.Minimal clinically important differences in the Carpal Tunnel… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.